4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2% – What’s Next?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s stock price rose 6.2% during trading on Wednesday . The company traded as high as $10.98 and last traded at $10.7150. Approximately 426,187 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 857,576 shares. The stock had previously closed at $10.09.

Analyst Upgrades and Downgrades

FDMT has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Chardan Capital upped their price target on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Finally, Roth Capital lowered their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Stock Performance

The company has a market cap of $613.92 million, a P/E ratio of -2.86 and a beta of 2.96. The stock has a 50-day simple moving average of $9.46 and a 200 day simple moving average of $6.40.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 2,678 shares of the company’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the sale, the insider owned 3,594 shares of the company’s stock, valued at $43,128. The trade was a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 9,128 shares of company stock worth $92,100. 9.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of the stock. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics during the third quarter valued at $41,000. Farther Finance Advisors LLC increased its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares in the last quarter. Abich Financial Wealth Management LLC bought a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $80,000. Inscription Capital LLC acquired a new position in 4D Molecular Therapeutics in the third quarter valued at about $94,000. Finally, Impact Partnership Wealth LLC bought a new stake in 4D Molecular Therapeutics during the third quarter worth about $96,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.